Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 157

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 157
---
 As of the date of this Proxy Statement/Prospectus, none of Enfusion’s executive officers has had any discussions or negotiations, or entered into any agreement, with Clearwater or any of its affiliates regarding the potential terms of their individual employment agreements or the right to participate in the equity of Clearwater or one or more of its affiliates following the consummation of the Transactions. Prior to or following the Closing of the Transactions, however, certain executive officers may have discussions, or may enter into agreements with, Clearwater or its affiliates regarding employment with, or the right to participate in the equity of, Clearwater or one or more of its affiliates. Accounting Treatment of the Transactions Clearwater and Enfusion prepare their financial statements in accordance with GAAP. The Transactions will be accounted for using the acquisition method of accounting in accordance with FASB ASC Topic 805, Business Combinations, with Clearwater considered as the accounting acquirer and Enfusion as the accounting acquiree. Accordingly, consideration to be given by Clearwater to complete the Transactions will be allocated to the identifiable tangible and intangible assets acquired and liabilities assumed of Enfusion based on their estimated fair values as of the date of the completion of the Merger, with any excess Merger Consideration being recorded as goodwill. Material U.S. Federal Income Tax Consequences of the Corporate Mergers The following general discussion sets forth the anticipated material U.S. federal income tax consequences of the Merger and, if the Second Merger Conditions are satisfied, the Second Merger, to Enfusion Stockholders and the ownership and disposition of any Clearwater Common Stock received by U.S. Holders (as defined below) in the Merger. This discussion is based on the Code, the Treasury Regulations, judicial authority and administrative rulings, all as of the date of this Proxy Statement/Prospectus, and all of which are subject to change, possibly with retroactive effect, and to differing interpretations. No ruling has been or is expected to be sought from the IRS with respect to any of the U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to an Enfusion Stockholder as a result of the Corporate Mergers or as a result of the ownership and disposition of any Clearwater Common Stock received in the Merger. This